ABL Bio to Participate in 'Bio Europe 2023'... Discussing Collaboration Plans with Big Pharma

ABL Bio announced on the 6th that it will participate in 'Bio Europe 2023,' held from the 6th to the 8th (local time) in Munich, Germany.

ABL Bio CI. [Image provided by ABL Bio]

Bio Europe is one of the biotechnology and bio-specialized exhibitions attended by pharmaceutical and bio companies and industry experts worldwide. It is held twice a year, divided into spring and autumn events, with the spring Bio Europe 2023 having been held at Messe Basel, Switzerland, this past March.

At this event, ABL Bio will meet with global big pharma companies to introduce clinical and non-clinical data of bispecific antibody anticancer drugs and discuss various cooperation plans, including technology transfer and joint development.

ABL Bio will share the recently announced interim results of Phase 1 clinical trials for 'ABL111' and 'ABL503' with global big pharma companies with whom discussions have been ongoing. For companies focusing on developing treatments for degenerative brain diseases, ABL Bio plans to introduce its blood-brain barrier (BBB) shuttle platform, 'Grabody-B.'

Lee Sang-hoon, CEO of ABL Bio, said, "As pipelines in clinical stages increase, opportunities to introduce the company's technology are naturally increasing. At this year's Bio Europe, we plan to share safety and efficacy data recently confirmed in clinical trials, discuss partnerships, and grasp global new drug development trends to prepare for the future."

This content was produced with the assistance of AI translation services.